• InterView
• “34 years in drug industry, but now as a law firm advisor"
• by Eo, Yun-Ho Jan 28, 2021 05:59am

• InterView
• “PARP inhibitor as backbone in ovarian cancer treatment”
• by Eo, Yun-Ho Dec 9, 2020 10:54am

• InterView
• “30-year-old Novarsc is our pride”
• by Eo, Yun-Ho Nov 17, 2020 06:26am

• InterView
• Pfizer in the center of autoimmune disease treatment scene
• by Eo, Yun-Ho Oct 8, 2020 06:24am

• InterView
• The corporation separation is started from Employee rights
• by Sep 7, 2020 06:12am

• InterView
• KRPIA “Narrowing the gap with gov. on appropriate pricing"
• by Eo, Yun-Ho Aug 31, 2020 05:57am

• InterView
• AlphaGo will lead the development of new drugs
• by Nho, Byung Chul Jul 14, 2020 06:12am

• InterView
• Post-corona KSC academic conference finds answer in hybrid
• by An, Kyung-Jin Jul 8, 2020 05:37am

• InterView
• EASY-ON opens up new opportunity to Xarelto amid COVID-19
• by Eo, Yun-Ho Jun 19, 2020 06:24am

• InterView
• Why is Metformin’s investigation expanded?
• by Lee, Tak-Sun Jun 12, 2020 06:11am